COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis

COUR Pharmaceuticals announced the US FDA granted Fast Track Designation to the company’s investigational therapy CNP-104 for the treatment of primary biliary cholangitis.